reason report
focu pt
bottom line continu believ attract
turnaround still earli inning compel valuat
stock remain top larg cap med-tech pick --
especi revenue ep growth acceler set take form
meaning way head current price-to-earnings
level -- -one cheapest among large-cap med-tech -- -we think
multipl gradual move higher given clearer pathway emerg
around revenue growth acceler margin improv
faster hsd ep growth throughout move
defens manag suppli issu offens new product launch
continu unfold -- -i rosa tka persona cementless knee rosa
one spine effort pick along
management newli announc restructur plan confid increas
long-term revenue ep growth acceler potenti out-year
earnings/fcf power pt goe vs prior appli
slightli higher vs prior multipl -- -given confid
ep growth acceler prospect -- consensu
out-performance sale y/i cc beat
consensu slightli consensu basi
reflect top-lin growth weight averag market growth rate
wamgr estim cc revenue growth cc sell
day adj beat our/consensu cc estim rel
consensu upsid came ww knee
modest upsid ww hip spine cmf
dental set came slightli consensu
apac drove signific upsid ww hips/kne gm
ahead consensu ebita margin
compar consensu ultim ep beat
oper upsid better expect
deliv anoth qtr ww cc knee growth
acceler sell day adj vs sell day adj
help increment rosa knee capit
driven persona includ recent launch revis system
rosa knee capit also acceler drove littl
ww y/i growth us knee growth also acceler
estim us rosa capit revenue qtr us placement vs
estim us placement exclud rosa
estim us core knee growth vs
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
cash ep
year price history/av daili volume mil
compani inform svb leerink llc research
million ep ex-amort
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
estim us core knee growth
still market rate continu narrow spread
encourag model us knee growth acceler
continu close gap market rate model
us knee growth vs inclus robot capit
contribut think estim could conserv time
grow robot instal base continu gener increas
implant revenue momentum well model robot revenue unit
increas unit unit
rev/adj ep bracket street report cc
revenue growth rang y/i came us/consensu
midpoint growth contempl neg fx
impact littl bit larger neg impact vs
off-set slight posit impact neutral impact full
year addit sell day materi impact
sell day remain qtr gm expect see downward
pressur y/i expect slightli higher adj
ebita margin expect rang captur
street near midpoint consensu income/expens
like return histor slightli neg level vs slightli
posit number adj tax rate expect adj
ep guidanc came consensu
midpoint expect burden
restructur charg anticip end
restructur initi expect reduc cost drive
increas leverag earn power year
compani reorgan busi unit creat greater strateg
align increas effici improv resourc alloc
acceler revenue growth adj op margin improv next
year compani estim one-tim cost
yield gross annual adj pre-tax op-ex save
help deliv op mgn expans least time
period vs current y/i margin improv linear
howev model y/i increas y/i
thu back-end weight trajectori could
upsid forecast depend time invest opportun
think like activ tuck-in front
next month
model updat revenu increas
y/i cc y/i respect reflect
results/upsid guidanc adj oper margin increas
vs prior reflect modest y/i margin expans
vs expans prior continu model
y/i expans vs prior adj ep
unchang estim increas
rate zimmer hold nyse outperform pt view strong
turnaround stori make new leadership think compani improv
execut eventu drive faster ep growth compani come side
manufactur suppli recoveri post re-acceler top line given potenti
may even begin engag portfolio re-shap beyond
shift exposur toward faster-grow end-mkts/subseg end day
gener solid hold market-lead posit across key orthoped market
favor demograph tailwind trade signific price-to-earnings p/
 discount large-cap med-tech think zbh steep discount vs peer narrow
compani improv execut eventu drive faster ep growth
trade fairli steep discount large-cap med-tech group forward
price-to-earnings average believ level discount vs large-cap peer warrant given
average top-lin growth think current discount vs peer vs wide
believ ultim busi time capabl gener hsd
ep growth gradual top-lin acceler mid-singl digit growth territori reflect
acceler top bottom line growth profil think allow zbh multipl
continu close gap vs peer pt vs prior assum trade
ep narrow valuat gap vs large-cap med-tech
average forward multipl would zbh current price-to-earnings multipl would
still repres discount large-cap exclud ew
group average price-to-earnings compani large-cap group includ alc
snn think multipl expans justifi given
risk valuat includ abl execut post-biomet ldrh deal
synergi guidanc take longer address suppli issu build safeti
stock inventori -- -which could limit co abil meet demand and/or regain market share futur
qtr crucial sale growth acceler stori underli ortho recon growth
rate slow vs current expect level price eros industri ortho recon price
occur dramat pace expect wors steadi y/i declin
rang unabl off-set asp price declin posit mix benefit relat new
product offer could hinder long-term share price appreci
robot total knee categori begin acceler faster-than-expect and/or abl
capit rosa knee applic time fashion fda approv
million except ep
compani report streetaccount consensu svb leerink llc research
million except ep
compani report svb leerink llc estim
neutral full year
skew fx current rate throughout
yr somewhat larger neg impact littl
larger off-set slight posit
benefit addit bill day
materi impact expect remain quarter
slightli higher remain qtr y/i
like return histor level -- slightli neg
number -- bar anoth qtr unusu posit item
incl restructur charg management
expect littl half charg
compani report svb leerink llc estim
dollar million except per share data
product sold ex-intang amort
research develop expens
sell gener administr expens
income/ loss attribut non-controlling inter
adj dilut averag share million
gross margin ex devic tax
oper expens sale
sg sale
 sale
compani data svb leerink llc estim
note restat certain incom statement item reflect adopt account standard updat revenu contract custom topic account standard updat
dollar million
total sale adjust divestitur
y/i growth organ adjust cc da
y/i growth pro-forma adjust cc day
dollar million
compani report svb leerink llc estim
note restat certain incom statement item reflect adopt account standard updat revenu contract custom topic account standard updat
